Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection

Uriel Sandkovsky, Susan Swindells, Brian L. Robbins, Sarah R. Nelson, Edward P. Acosta, Courtney V. Fletcher

Research output: Contribution to journalArticle

8 Scopus citations


Paired plasma and intracellular samples were obtained from 12 HIV-infected adults taking raltegravir twice daily (b.i.d.), and after switching to once daily. With b.i.d. dosing, no plasma trough concentrations were below the IC95, in contrast to 33% for once daily dosing. Fifty percent of the once daily group had intracellular trough concentrations below the inhibitory concentration 95 (IC95), 25% in the b.i.d. group. Lower plasma and intracellular concentrations may contribute to inferior virologic suppression rates observed with once daily raltegravir dosing.

Original languageEnglish (US)
Pages (from-to)2257-2259
Number of pages3
Issue number17
StatePublished - Nov 13 2012


ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this